Given high costs and low success rates, risk mitigation strategies are critical in drug development. Pharmaceutical companies and investors are continually looking for ways to minimise clinical
development risk. One opportunity for reducing risk in a drug development programme is through the integration of central haemodynamic assessments – arterial stiffness and central blood
pressure waveform assessments – into clinical trial protocols. Salman Sher at ECCRI and Bobby Stutz at AtCor Medical Inc. explains that the central haemodynamic assessments can easily be incorporated into any study visit workflow and the results provide incremental, clinically meaningful information about clinical trial subjects’ physiology and their responses to intervention.